Alle Storys
Folgen
Keine Story von Curasan AG mehr verpassen.

Curasan AG

euro adhoc: curasan AG
Quarterly or Semiannual Financial Statements / Revenue increase of 51 per cent in Q3 2004 Readjustment of revenue and earnings forecast for 2004

Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
Kleinostheim, November 9, 2004 – curasan AG (WKN 549 453) today
announced its preliminary results for the first nine months ended
September 30, 2004. As regards year-on-year comparisons, it should be
noted that the Pharmaceuticals business unit (Anti-Infectives and
AIEP products) was sold by the company in October 2003 and that
curasan is currently focusing on the area of Regenerative Medicine.
In the first nine months of 2004, revenues generated by continuing
operations increased by 34%, up from EUR 4.3 million to EUR 5.8
million. In the same period a year ago, total revenue, including that
generated within the Pharmaceuticals unit now no longer operated by
the company, had amounted to EUR 12.8 million. The loss before
interest and taxes for the remaining business unit was reduced from
EUR 3.5 million to EUR 2.3 million. As a result of corporate
streamlining, the total headcount stood at 74 at the end of the
quarter, compared with 95.
The company recorded a year-on-year revenue increase of 51% in the
third quarter of the 2004 financial year. However, third-quarter
performance fell short of the targets originally set by curasan. The
Biomaterials business unit, in particular, performed at a level that
was well below the specified target. The company has yet to offset
the shortfall in revenues attributable to a change in its
distribution structure in the US. Based on current sales figures and
the backlog of orders as at October 2004, the Management Board is of
the opinion that the company’s target of EUR 10 million in revenues
and minus EUR 0.5 million in earnings will not be met, or exceeded,
until 2005.
The company’s forecast for the full 2004 financial year has been
adjusted to approx. EUR 8 million in terms of revenues generated and
a net loss of EUR 2 million.
The full quarterly report can be accessed on November 11, 2004, at
www.curasan.de, Investor Relations section.
End of Ad hoc-Release
About curasan AG:
curasan AG (ISIN: DE 000 549 453 8), an exchange-listed company, is a
leading innovator within the growth market of bone and tissue
regeneration. The company has developed a comprehensive product range
centred around its synthetic bone regeneration material Cerasorb®,
for use in soft and hard tissue. curasan AG's main goal is to occupy
a leading position as a global specialist in Regenerative Medicine.
For further information, please visit curasan’s corporate website at:
www.curasan.de
end of announcement                    euro adhoc 09.11.2004 08:14:10 

Further inquiry note:

Ralph Wintermantel, curasan AG, Tel. 06027/46 86 468, eMail:
ir@curasan.de
Dr. Erwin Amashaufer, curasan AG, Tel. 06027/46 86 0, eMail:
ir@curasan.de

Branche: Biotechnology
ISIN: DE0005494538
WKN: 549453
Index:
Börsen: Bayerische Börse / free trade
Baden-Württembergische Wertpapierbörse / Regulated free trade

Original-Content von: Curasan AG, übermittelt durch news aktuell

Weitere Storys: Curasan AG
Weitere Storys: Curasan AG